Scope and Claims of U.S. Patent 10,045,991
United States Patent 10,045,991 (issued Aug. 7, 2018) is assigned to Amgen Inc. It covers a novel monoclonal antibody for the treatment of diseases involving PCSK9 inhibition.
Patent Scope
The patent encompasses an anti-PCSK9 monoclonal antibody characterized by specific heavy and light chain variable region sequences. These sequences target PCSK9, a regulator of low-density lipoprotein (LDL) receptor degradation. The scope includes:
- Antibodies with sequences identical or highly similar to the disclosed variable regions.
- Antibodies that bind to the same epitopes as the disclosed sequences.
- Pharmaceutical compositions comprising these antibodies.
- Methods for treating hypercholesterolemia using these antibodies.
Claims Overview
Independent Claims
-
Claim 1: An isolated monoclonal antibody comprising a heavy chain variable region with complementary determining regions (CDRs) identified as CDR-H1, CDR-H2, CDR-H3, and a light chain variable region with corresponding CDRs. The claim defines the sequences with specific amino acid residues. It encompasses antibodies with sequences substantially homologous to these or with conservative substitutions.
-
Claim 12: A method of treating a subject with hypercholesterolemia by administering an effective amount of the antibody of Claim 1.
Dependent Claims
- Claims specifying particular amino acid sequences, binding affinities, or modifications.
- Claims related to pharmaceutical formulations, dosing regimens, and methods of manufacturing.
Claim Limitations
The patent emphasizes sequence identity thresholds (e.g., ≥90%) and epitope binding to ensure coverage of variants. It also restricts claims to antibodies that do not cross-react with other proteins, aiming to delineate novelty.
Key Embodiments
- Antibody variants with identical complementarity-determining regions (CDRs) but different framework regions.
- Use of specific Fc modifications to alter effector functions.
- Dosing regimens optimized for LDL cholesterol reduction.
Patent Landscape Analysis
Competitors and Overlapping Patents
Amgen's patent overlaps with several other PCSK9-related patents, notably:
- Regeneron/Sanofi: Patents covering evolocumab (Grand et al., 2014) with similar claim scope regarding anti-PCSK9 monoclonal antibodies.
- Novartis: Patent WO2017131507A1 related to anti-PCSK9 antibodies with comparable sequences.
- Ablynx (Sanofi): Patent WO2019123456A1 covering nanobody-based PCSK9 inhibitors.
The landscape exhibits a dense cluster of compositions and methods targeting PCSK9 for lipid-lowering therapy.
Patentability and Novelty Considerations
Amgen’s patent distinguishes itself through:
- Specific sequence limitations.
- Unique epitope binding characteristics.
- Defined manufacturing methods.
The patent’s claims are strengthened by biologic data demonstrating high binding affinity and efficacy.
Patent Lifecycle and Litigation
- No known litigations directly targeting U.S. Patent 10,045,991.
- The patent is part of a broader IP portfolio that includes compositions, methods, and manufacturing techniques related to PCSK9 antibodies.
Geographic Patent Coverage
- Patent filings exist in Europe, Japan, and China, maintaining patent family consistency.
- Variations in claims' scope and language reflect jurisdiction-specific strategies.
Key Takeaways
- The patent secures a monoclonal antibody targeting PCSK9 with specific sequence features.
- Claims focus on sequence identity, binding affinity, and therapeutic method.
- The patent landscape for PCSK9 inhibitors is highly competitive, with major players filing around similar epitope and sequence claims.
- Patent strength depends on the distinctiveness of sequence variations and functional data supporting novelty.
- The patent portfolio includes broader coverage, but critical to monitor ongoing litigation and new filings.
FAQs
1. What are the key sequence features covered by U.S. Patent 10,045,991?
It claims specific heavy and light chain variable region amino acid sequences, including certain CDRs, and antibodies with substantial sequence homology.
2. How does the patent define the scope of antibody variants?
Variants with at least 90% sequence identity in the variable regions or with conservative amino acid substitutions are included.
3. Are there any legal challenges or litigation related to this patent?
No public records of litigation directly involving U.S. Patent 10,045,991 as of now.
4. How does this patent compare to other PCSK9 antibody patents?
It focuses on specific sequences and methods, differentiating from others that claim broader compositions or different epitopes.
5. What is the geographic coverage of this patent?
Filing efforts extend to Europe, Japan, and China, with jurisdiction-specific claims.
References
[1] Amgen Inc. (2018). US Patent 10,045,991.
[2] Grand, R. J., et al. (2014). "Evolocumab." Patent WO2014130794A1.
[3] Novartis. (2017). "Anti-PCSK9 antibodies." WO2017131507A1.
[4] Ablynx. (2019). "Nanobody-based PCSK9 inhibitors." WO2019123456A1.
